Every material Form 8-K CytomX Therapeutics, Inc. has filed with the SEC since July 27, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
CytomX reported unaudited third-quarter 2026 results with revenue of $1.7 million, down from $6.0 million a year earlier, as the Astellas collaboration performance obligation concluded in the second quarter of 2026. The net loss widened to $20.0 million from $14.2 million, while operating expenses rose to $25.2 million, and the company ended the quarter with $348.0 million in cash, cash equivalents and investments, with cash runway expected into the second half of 2028.
Q3 2026 revenue was $1.7 million versus $6.0 million in Q3 2025; nine-month revenue was $13.4 million versus $75.5 million.
Q3 2026 net loss was $20.0 million, or $0.09 per share, versus a net loss of $14.2 million, or $0.09 per share, a year earlier.
Operating expenses rose to $25.2 million from $21.7 million, led by research and development at $16.5 million and general and administrative at $8.7 million.
Varseta-M received FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer in August 2026; a Phase 1 monotherapy data update is expected in January 2027.
CytomX Therapeutics reported unaudited second-quarter 2026 results. Revenue fell to $1.4 million from $18.7 million a year earlier, and the company posted a net loss of $20.7 million, compared with a $154 thousand loss in the prior-year quarter, as operating expenses rose to $25.2 million. For shareholders, the shrinking revenue base and higher spending are partly offset by $330.3 million in cash and investments and a $37.0 million Regeneron payment received in July 2026.
Revenue was $1.4 million for the quarter ended June 30, 2026, versus $18.7 million in Q2 2025; the company cited completed collaboration obligations with Bristol Myers Squibb and the Astellas collaboration concluding in Q2 2026.
Net loss was $20.7 million, or $0.09 per share, versus a net loss of $154 thousand, or $0.00 per share, in Q2 2025.
Operating expenses rose to $25.2 million from $19.9 million, led by research and development costs of $17.6 million.
Cash, cash equivalents and investments were $330.3 million at June 30, 2026, down from $346.7 million at March 31, 2026; the company expects cash runway to at least the second half of 2028.
CytomX Therapeutics appointed Dr. Charles Fuchs to its Board of Directors effective July 24, 2026, as a Class II director with a term running to the 2029 annual meeting. The filing says he received an option to buy 118,000 shares of common stock, vesting monthly over three years, which ties part of his pay to the stock price.
Charles Fuchs, M.D., M.P.H., joined the board effective July 24, 2026, as a Class II director.
His initial term expires at the 2029 annual meeting of stockholders.
He received an option to purchase 118,000 shares at the July 24, 2026 closing price, vesting in 1/36th installments monthly.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CytomX Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →